423 related articles for article (PubMed ID: 30026337)
1. PD-L1
Pollari M; Brück O; Pellinen T; Vähämurto P; Karjalainen-Lindsberg ML; Mannisto S; Kallioniemi O; Kellokumpu-Lehtinen PL; Mustjoki S; Leivonen SK; Leppä S
Haematologica; 2018 Nov; 103(11):1908-1914. PubMed ID: 30026337
[TBL] [Abstract][Full Text] [Related]
2. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
[TBL] [Abstract][Full Text] [Related]
3. PD-L1 and PD-L2 Are Differentially Expressed by Macrophages or Tumor Cells in Primary Cutaneous Diffuse Large B-Cell Lymphoma, Leg Type.
Menguy S; Prochazkova-Carlotti M; Beylot-Barry M; Saltel F; Vergier B; Merlio JP; Pham-Ledard A
Am J Surg Pathol; 2018 Mar; 42(3):326-334. PubMed ID: 29112015
[TBL] [Abstract][Full Text] [Related]
4. PD-L1 and PD-L2 expression in the tumor microenvironment including peritumoral tissue in primary central nervous system lymphoma.
Furuse M; Kuwabara H; Ikeda N; Hattori Y; Ichikawa T; Kagawa N; Kikuta K; Tamai S; Nakada M; Wakabayashi T; Wanibuchi M; Kuroiwa T; Hirose Y; Miyatake SI
BMC Cancer; 2020 Apr; 20(1):277. PubMed ID: 32248797
[TBL] [Abstract][Full Text] [Related]
5. Characterisation of tumour microenvironment and immune checkpoints in primary central nervous system diffuse large B cell lymphomas.
Alame M; Pirel M; Costes-Martineau V; Bauchet L; Fabbro M; Tourneret A; De Oliveira L; Durand L; Roger P; Gonzalez S; Cacheux V; Rigau V; Szablewski V
Virchows Arch; 2020 Jun; 476(6):891-902. PubMed ID: 31811434
[TBL] [Abstract][Full Text] [Related]
6. Ratios of T-cell immune effectors and checkpoint molecules as prognostic biomarkers in diffuse large B-cell lymphoma: a population-based study.
Keane C; Vari F; Hertzberg M; Cao KA; Green MR; Han E; Seymour JF; Hicks RJ; Gill D; Crooks P; Gould C; Jones K; Griffiths LR; Talaulikar D; Jain S; Tobin J; Gandhi MK
Lancet Haematol; 2015 Oct; 2(10):e445-55. PubMed ID: 26686046
[TBL] [Abstract][Full Text] [Related]
7. T-cell inflamed tumor microenvironment predicts favorable prognosis in primary testicular lymphoma.
Leivonen SK; Pollari M; Brück O; Pellinen T; Autio M; Karjalainen-Lindsberg ML; Mannisto S; Kellokumpu-Lehtinen PL; Kallioniemi O; Mustjoki S; Leppä S
Haematologica; 2019 Feb; 104(2):338-346. PubMed ID: 30237271
[TBL] [Abstract][Full Text] [Related]
8. MiR155 sensitized B-lymphoma cells to anti-PD-L1 antibody via PD-1/PD-L1-mediated lymphoma cell interaction with CD8+T cells.
Zheng Z; Sun R; Zhao HJ; Fu D; Zhong HJ; Weng XQ; Qu B; Zhao Y; Wang L; Zhao WL
Mol Cancer; 2019 Mar; 18(1):54. PubMed ID: 30925928
[TBL] [Abstract][Full Text] [Related]
9. PD-1/PD-L1 expression and tumor-infiltrating lymphocytes are prognostically favorable in advanced high-grade serous ovarian carcinoma.
Martin de la Fuente L; Westbom-Fremer S; Arildsen NS; Hartman L; Malander S; Kannisto P; Måsbäck A; Hedenfalk I
Virchows Arch; 2020 Jul; 477(1):83-91. PubMed ID: 31980961
[TBL] [Abstract][Full Text] [Related]
10. Immune Profiling and Quantitative Analysis Decipher the Clinical Role of Immune-Checkpoint Expression in the Tumor Immune Microenvironment of DLBCL.
Xu-Monette ZY; Xiao M; Au Q; Padmanabhan R; Xu B; Hoe N; Rodríguez-Perales S; Torres-Ruiz R; Manyam GC; Visco C; Miao Y; Tan X; Zhang H; Tzankov A; Wang J; Dybkær K; Tam W; You H; Bhagat G; Hsi ED; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; van Krieken JH; Winter JN; Westin JR; Pham LV; Medeiros LJ; Rassidakis GZ; Li Y; Freeman GJ; Young KH
Cancer Immunol Res; 2019 Apr; 7(4):644-657. PubMed ID: 30745366
[TBL] [Abstract][Full Text] [Related]
11. PD-1/PD-L1 expression and interaction by automated quantitative immunofluorescent analysis show adverse prognostic impact in patients with diffuse large B-cell lymphoma having T-cell infiltration: a study from the International DLBCL Consortium Program.
Li L; Sun R; Miao Y; Tran T; Adams L; Roscoe N; Xu B; Manyam GC; Tan X; Zhang H; Xiao M; Tzankov A; Visco C; Dybkaer K; Bhagat G; Tam W; Hsi ED; van Krieken JH; You H; Huh J; Ponzoni M; Ferreri AJM; Møller MB; Piris MA; Zhang M; Winter JN; Medeiros LJ; Rassidakis GZ; Vaupel CA; Li Y; Dakappagari N; Xu-Monette ZY; Young KH
Mod Pathol; 2019 Jun; 32(6):741-754. PubMed ID: 30666052
[TBL] [Abstract][Full Text] [Related]
12. Adverse prognostic impact of regulatory T-cells in testicular diffuse large B-cell lymphoma.
Pollari M; Pellinen T; Karjalainen-Lindsberg ML; Kellokumpu-Lehtinen PL; Leivonen SK; Leppä S
Eur J Haematol; 2020 Dec; 105(6):712-721. PubMed ID: 32632935
[TBL] [Abstract][Full Text] [Related]
13. Immune evasion via PD-1/PD-L1 on NK cells and monocyte/macrophages is more prominent in Hodgkin lymphoma than DLBCL.
Vari F; Arpon D; Keane C; Hertzberg MS; Talaulikar D; Jain S; Cui Q; Han E; Tobin J; Bird R; Cross D; Hernandez A; Gould C; Birch S; Gandhi MK
Blood; 2018 Apr; 131(16):1809-1819. PubMed ID: 29449276
[TBL] [Abstract][Full Text] [Related]
14. An Immunoscore Using PD-L1, CD68, and Tumor-infiltrating Lymphocytes (TILs) to Predict Response to Neoadjuvant Chemotherapy in Invasive Breast Cancer.
McLemore LE; Janakiram M; Albanese J; Shapiro N; Lo Y; Zang X; Fineberg S
Appl Immunohistochem Mol Morphol; 2018 Oct; 26(9):611-619. PubMed ID: 28422766
[TBL] [Abstract][Full Text] [Related]
15. PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas.
Zhang S; Minaguchi T; Xu C; Qi N; Itagaki H; Shikama A; Tasaka N; Akiyama A; Sakurai M; Ochi H; Satoh T
BMC Cancer; 2020 Feb; 20(1):127. PubMed ID: 32066405
[TBL] [Abstract][Full Text] [Related]
16. Tumor Microenvironment and Checkpoint Molecules in Primary Cutaneous Diffuse Large B-Cell Lymphoma-New Therapeutic Targets.
Mitteldorf C; Berisha A; Pfaltz MC; Broekaert SMC; Schön MP; Kerl K; Kempf W
Am J Surg Pathol; 2017 Jul; 41(7):998-1004. PubMed ID: 28504999
[TBL] [Abstract][Full Text] [Related]
17. Clinicopathological analysis of programmed cell death 1 and programmed cell death ligand 1 expression in the tumour microenvironments of diffuse large B cell lymphomas.
Kwon D; Kim S; Kim PJ; Go H; Nam SJ; Paik JH; Kim YA; Kim TM; Heo DS; Kim CW; Jeon YK
Histopathology; 2016 Jun; 68(7):1079-89. PubMed ID: 26426431
[TBL] [Abstract][Full Text] [Related]
18. PD-L1 Expression and a High Tumor Infiltrate of CD8+ Lymphocytes Predict Outcome in Patients with Oropharyngeal Squamous Cells Carcinoma.
Wuerdemann N; Gültekin SE; Pütz K; Wittekindt C; Huebbers CU; Sharma SJ; Eckel H; Schubotz AB; Gattenlöhner S; Büttner R; Speel EJ; Klussmann JP; Wagner S; Quaas A
Int J Mol Sci; 2020 Jul; 21(15):. PubMed ID: 32718057
[TBL] [Abstract][Full Text] [Related]
19. PD-L1 expression is associated with tumor-infiltrating T cells and favorable prognosis in high-grade serous ovarian cancer.
Webb JR; Milne K; Kroeger DR; Nelson BH
Gynecol Oncol; 2016 May; 141(2):293-302. PubMed ID: 26972336
[TBL] [Abstract][Full Text] [Related]
20. Tumor-infiltrating immune cell subpopulations and programmed death ligand 1 (PD-L1) expression associated with clinicopathological and prognostic parameters in ependymoma.
Nam SJ; Kim YH; Park JE; Ra YS; Khang SK; Cho YH; Kim JH; Sung CO
Cancer Immunol Immunother; 2019 Feb; 68(2):305-318. PubMed ID: 30483834
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
